Medicina
Departamento
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (91)
2024
-
Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835
-
Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Frontiers in Neurology, Vol. 15
-
Lack of awareness of systemic lupus erythematosus and its consequences in a cohort of moderate and severe patients in Spain: The LupusVoice study
Lupus
-
Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines
American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10
2023
-
Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction
Journal of Clinical Medicine, Vol. 12, Núm. 6
-
Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811
-
Differences in clinical outcomes, health care resource utilization and costs in heart failure patients according to left ventricular ejection fraction
Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 862-871
-
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Journal of Clinical Oncology, Vol. 41, Núm. 1, pp. 43-53
-
Evolution of economic burden of heart failure by ejection fraction in newly diagnosed patients in Spain
BMC Health Services Research, Vol. 23, Núm. 1
-
Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome
American Heart Journal, Vol. 264, pp. 20-30
-
Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068
-
Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study
Cancers, Vol. 15, Núm. 16
-
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1759-1770.e7
2022
-
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
HemaSphere, Vol. 6, Núm. 12, pp. E801
-
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial
European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 8, pp. 777-785
-
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1415-1427
-
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
ESMO Open, Vol. 7, Núm. 2
-
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study
Gynecologic Oncology, Vol. 165, Núm. 1, pp. 40-48
-
Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study
Revista Espanola de Cardiologia, Vol. 75, Núm. 1, pp. 31-38
-
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311